Listen to article
7:15Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
Let’s be honest, nobody enjoys a trip to the doctor. The whole affair is often a grim procession of prodding, scanning, and waiting for results that feel like they’re delivered by carrier pigeon. When it comes to detecting cancer, the process can be particularly medieval. It often involves invasive biopsies, where a piece of you is literally carved out for inspection, a procedure that happens only after the disease has likely made itself comfortable. I’ve often thought there must be a better way, and it seems, finally, there might be.
The big idea is called a liquid biopsy. It sounds futuristic, but the concept is beautifully simple. Think of it like this, tumours, the unwelcome squatters in our bodies, are messy tenants. They shed bits of their DNA and other cellular debris into the bloodstream. For years, this biological litter was just noise. Now, thanks to some rather clever technology, scientists can analyse a simple vial of blood and spot these tell-tale signs of cancer.
This isn't just about avoiding an uncomfortable procedure. It’s about time. These tests could potentially detect cancer months, or even years, before a person would typically show symptoms. And in the fight against cancer, time is the only currency that truly matters. Catching it early dramatically improves survival rates and, not to be overlooked, significantly reduces the eye-watering costs of treatment. For an investor, that intersection of better patient outcomes and lower healthcare bills is, to put it mildly, quite compelling.
As with any revolution, there are pioneers leading the charge. You have companies like Guardant Health, which has developed tests that act like a reconnaissance drone, scanning the blood for dozens of cancer-associated genes to help doctors choose the right treatment. Then you have firms like Exact Sciences, which first changed the game in colorectal cancer screening and is now applying that same disruptive thinking to blood-based tests for multiple cancers.
To me, this isn't just a story about science. It's a story about strategy. Each company is placing its bets, developing its own technology, and fighting for the trust of regulators and doctors. They are building what the business school types call ‘competitive moats’, using sophisticated science and vast amounts of data to create barriers that are difficult for newcomers to overcome. It’s a high stakes game, but the potential prize is a slice of a multi-billion pound global diagnostics market.
The real driver here is cold, hard economics. Treating a Stage I cancer might cost tens of thousands of pounds. Treating that same cancer at Stage IV can run into the hundreds of thousands, a devastating financial blow to healthcare systems and families. A liquid biopsy test that costs a few hundred pounds and enables early detection doesn't just look like good medicine, it looks like an exceptional bargain.
This is why insurers and public health systems are beginning to pay attention. The potential for cost savings is enormous, which could accelerate adoption far quicker than one might expect. It’s this compelling economic logic that has drawn attention to a whole host of companies, a group you might call The Blood Test Revolution, all vying for a piece of this enormous pie.
Now, let’s not get carried away. Investing in this space is not for the faint of heart. The path to success is littered with landmines. A single failed clinical trial or an unexpected rejection from regulators can send a company’s share price into a nosedive overnight. Competition is also becoming fierce, as the established giants of the pharmaceutical world are now waking up to the opportunity and either developing their own tests or simply buying up the smaller innovators.
Furthermore, the technology itself still has hurdles to clear. A false positive could cause immense anxiety and lead to unnecessary procedures, while a false negative might offer a dangerously false sense of security. Getting these tests to be near-perfect is a monumental technical challenge. While the potential is undeniable, the risks are just as real, and any investor should approach this sector with their eyes wide open.
View the full Basket:Liquid-Biopsy Diagnostics
View the full Basket:Liquid-Biopsy Diagnostics
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
